Background {#Sec1}
==========

The bacterium *Staphylococcus aureus* causes a variety of infections, ranging from skin and soft tissue infections to life-threatening disease \[[@CR1]\]. It is also a commensal that colonises the anterior nares of asymptomatic carriers, who may unknowingly transmit the pathogen within the community or within healthcare facilities \[[@CR2]\]. Carriage among healthcare workers (HCW) may act as a source of infection in hospitals \[[@CR3]\]. Since the introduction of *β*-lactam antibiotics, the spread of methicillin-resistant *S. aureus* (MRSA) has increased on a global scale \[[@CR4], [@CR5]\].

Data regarding the prevalence and distribution of methicillin-sensitive *S. aureus* (MSSA) and MRSA in Africa are scarce, and control measures within healthcare settings are limited due to constraints with respect to resources and diagnostic facilities \[[@CR6]\]. Studies on *S. aureus* carriage by hospital patients in Madagascar report a MRSA prevalence of between 4 and 13 % \[[@CR7]--[@CR11]\]. The prevalence of *S. aureus* nasal carriage in outpatients was 38, and 15 % of cases were MRSA \[[@CR7]\]. Madagascan hospitals set no guidelines for screening patients or HCW for MRSA.

Different MRSA strains have emerged in hospitals and in the community in both Europe and the USA \[[@CR12], [@CR13]\]. Factors such as travel and close contact with animals may contribute to the dissemination of the bacterium in Africa: one MRSA clone in particular (ST-88-MRSA), which is found worldwide, is also widespread in West, Central, and East Africa \[[@CR14]\]. A multicentre study conducted across five different African countries identified one major clone, which is also predominant in Madagascar (ST-88 IV, *spa* type t186) \[[@CR15]\]. A high prevalence of the staphylococcal virulence factor, Panton-Valentine leukocidin (PVL), was found in MSSA strains isolated from hospital patients from mainland Africa and the Western Indian Ocean region \[[@CR8], [@CR16], [@CR17]\]. Evidence suggests that PVL is associated with staphylococcal skin and soft tissue infections \[[@CR18]\]. No data are available on the presence of PVL in MSSA and MRSA isolates obtained from HCW in Madagascar. Another staphylococcal virulence factor, toxic shock syndrome toxin-1 (TSST-1), causes severe illness and multisystem clinical manifestations \[[@CR19]\]. Few studies report the prevalence of TSST-1 in healthy carriers from Africa; to date, no data are available with respect to Madagascan HCW \[[@CR20], [@CR21]\]. Resistance to *β*-lactam antibiotics (as in MRSA) is due to the acquisition of the *mecA* gene. In recent years, a similar gene termed *mecC* has been described, which is often not detected by routine laboratory tests because standard molecular methods usually focus only on detecting *mecA* \[[@CR22]\].

Here, we obtained nasal swabs from HCW from different hospitals and from healthy non-medical students at the University of Antananarivo. The aim was to identify the prevalence and local clonal epidemiology of *S. aureus* and MRSA in Madagascar.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This cross sectional study enrolled non-medical students from the University of Antananarivo and HCW from five different hospitals (University Children's Hospital, the surgery department at the University Gynaecological Hospital, the University Infectious Diseases department, a military hospital, and a private clinic for general and trauma surgery) and one dispensary in Antananarivo, Madagascar. HCW were defined according to the WHO definition \[[@CR23]\], which included all study participants working in a hospital. Hospital staff were informed and recruited during in-house training sessions, while university students were asked to participate during seminars and lectures.

Sample size calculation {#Sec4}
-----------------------

The required sample size to yield at least k = 5 MRSA isolates with about 90 % probability was estimated by assuming that the proportion of MRSA among *S. aureus* isolates was 5 %, and that 35 % of all sampled individuals were carrying *S. aureus*. Using the formula$$\documentclass[12pt]{minimal}
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the required minimum sample size was estimated at 526 per arm (HCW and non-medical university students).

Data and sample collection procedures {#Sec5}
-------------------------------------

After providing informed consent, demographic data (e.g., sex, age, home community) was collected via a questionnaire. Students were asked to name their faculty, and hospital employees were asked to describe their role and whether their work included regular contact with patients. Respondents were also asked about hospital admissions within the last 6 months, their history of antimicrobial treatment within the last 6 months, whether they lived in a student/healthcare staff hall, whether they nursed chronically ill relatives at home, whether they suffer from a chronic illness, and whether they had any acute skin diseases such as atopic dermatitis, psoriasis or chronic ulcers. As *S. aureus* colonises pets and livestock, the participants were asked whether they had contact with animals \[[@CR14]\]. After the participants filled in the questionnaire, they were instructed on how to collect a self-administered nasal swab.

Microbiological examination of nasal swabs in Madagascar {#Sec6}
--------------------------------------------------------

The study team demonstrated the technique used to obtain nasal samples using a sterile cotton-tipped swab (Copan Nasal Swab Transsystem®, Brescia, Italy) and provided assistance where necessary. The samples were then immediately transported to the study laboratory where bacteria were isolated as described below.

After incubation on Columbia blood agar (OXOID®, Vienna, Austria) for 18--24 h at 35--37 °C, the first step of the identification procedure involved examination of colony morphology and Gram staining. Suspected *S. aureus* colonies on the blood agar plate were tested for catalase and coagulase activity, and for latex agglutination (Staphytec plus, OXOID®) \[[@CR24]\]. *S. aureus* strains were tested for antibiotic susceptibility using the standard disc diffusion method on Mueller-Hinton Agar, according to current CLSI (Clinical and Laboratory Standards Institute) guidelines. Antibiotic susceptibility testing was done for the following locally available and prescribed antibiotics: penicillin, erythromycin, clindamycin, cotrimoxazole, and ampicillin/sulbactam. Cefoxitin was used as an MRSA screening agent.

*S. aureus* ATCC-25923, BAA 9176, and methicillin-resistant *S. aureus* ATCC-43300 were used as controls. *S. aureus* isolates were stored at −80 °C in Cryobank tubes (Cryobank, MAST®, Liverpool, UK) until shipment at -20 °C to the Bernhard Nocht Institute for Tropical Medicine, Germany, for molecular analyses. The QIAamp DNA Mini Kit (Qiagen®, Hilden, Germany) was used to extract DNA from all *S. aureus* isolates, according to the manufacturer's instructions.

Multiplex PCR to confirm *S. aureus* isolates {#Sec7}
---------------------------------------------

In Germany, all *S. aureus* isolates were further screened for *S. aureus*-specific (*nuc*), MRSA-specific (both *mecA* and *mecC*), and PVL and TSST-1 virulence genes by multiplex PCR. The primers used are listed in Additional file [1](#MOESM1){ref-type="media"}: Supporting Information Table S1.

PCR was performed using the Qiagen® multiplex PCR kit (ref. no.-201643). Only strains harbouring the *mecA* or *mecC* genes were classified as MRSA \[[@CR25]\].

*Staphylococcus* protein A gene (*spa*) typing of MRSA isolates {#Sec8}
---------------------------------------------------------------

To examine the clonal epidemiology of MRSA, all PCR-confirmed MRSA isolates were subjected to *spa* typing using the RidomStaphType standard protocol, followed by double-strand sequencing \[[@CR26]\]. Sequences were analysed using RidomStaphType version 2.2.1 software (Ridom Ltd., Würzburg, Germany). Associated multi-locus sequence types (MLST) were automatically allocated by the Ridom SpaServer according to the based-upon-repeat-pattern (BURP) algorithm (if sufficient data were available) \[[@CR27]\], or retrieved from the literature.

Treatment of MRSA-positive individuals {#Sec9}
--------------------------------------

If the nasal swabs tested positive for MRSA in Madagascar, the participant was offered treatment with Mupirocin (Turixin®) ointment to eradicate the nasal MRSA (treatment followed the guidelines set down by the Robert-Koch-Institute, Germany) \[[@CR28]\]. After treatment, further nasal swabs were taken to confirm successful decolonisation.

Statistical analyses {#Sec10}
--------------------

Pearson's χ^2^ test or Fisher's exact test was used to compare the frequency distribution of *S. aureus* and MRSA nasal carriage by HCW and non-medical students. Age, sex, occupation, and previous antimicrobial use were variables entered into a multivariable logistic regression model to assess their adjusted association with *S. aureus* carriage. Analyses were performed using Stata 12 (StataCorp LP, College Station, USA) software.

Results {#Sec11}
=======

Nasal swabs were taken from 863 HCW and 685 students. *S. aureus* was identified in 171 isolates (11.0 %), of which 20 (1.3 %) were MRSA (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Examination procedure for nasal swabs obtained from university students and healthcare workers. In a first step *S.aureus* were identified via PCR-screening for *nuc* genes and in a second step these *S.aureus* were screened for *mecA* and *mecC* genes allowing to differentiate between methicillin-resistant and methicillin-sensitive *Staphylococcus aureus*

The point prevalence of nasal *S. aureus* carriage was 91 (10.4 %) in the HCW group and 80 (11.4 %) in the student group. MRSA carriage was slightly higher in the HCW group (1.5 %) than in the student group (0.9 %).

Of the MSSA isolates, 7.3 % were susceptible to penicillin (Table [1](#Tab1){ref-type="table"}). Erythromycin-induced resistance to clindamycin was not detected in any of the MSSA or MRSA isolates.Table 1Antibiotic susceptibility of methicillin-sensitive and methicillin-resistant *Staphylococcus aureus*Susceptibility \[Frequency (%)\]Drug (AC^a^ μg)MSSA^b^ (*N* = 151)MRSA^c^ (*N* = 20)Cefoxitin (30)151(100)00Clindamycin (2)149(98.7)20(100)Cotrimoxazole (30)142(94.0)17(85.0)Erythromycin (15)114(75.5)12(60.0)Penicillin (10)11(7.3)00^a^AC: antibiotic concentration^b^Methicillin-sensitive *Staphylococcus aureus*^c^Methicillin-resistant *Staphylococcus aureus*

The prevalence of MRSA carriage was equal among groups of the same age, and increased with age (Table [2](#Tab2){ref-type="table"}). Overall, nasal carriage of *S. aureus* was more common in women (12.7 %) than in men (8.0 %). Carriage of *S. aureus* and MRSA was slightly higher in HCW that reported direct patient contact (Table [3](#Tab3){ref-type="table"}). *S. aureus* and MRSA carriage stratified according to medical profession or workplace is shown in Table [3](#Tab3){ref-type="table"}. There was no strong association between MRSA carriage and other risk factors (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). Multivariable logistic regression analyses identified female gender and age \> 25 years as significantly associated with nasal carriage of *S. aureus* (*p* = 0.003 and *p* = 0.04, respectively) (Table [6](#Tab6){ref-type="table"}).Table 2Prevalence of *Staphylococcus aureus* (*S. aureus*) and methicillin-sensitive (MSSA) and methicillin-resistant *Staphylococcus aureus* (MRSA) in healthcare workers and students in Antananarivo, Madagascar (*N* = 1548)Healthcare workers^a^Students*S. aureus*MSSAMRSA*S. aureus*MSSAMRSATotal number (N)n (%)n (%)*p* ^*b*^n (%)*p* ^*b*^Total number (N)n (%)n (%)*p* ^*b*^n (%)*p* ^*b*^Prevalence86391 (10.4)77 (8.9)\--14 (1.5)\--68580 (11.8)74 (10.8)\--6 (0.9)\--CharacteristicsAge\<25 years40333 (8.2)29 (7.2)0.114 (1.0)0.19\*60370 (11.5)65 (10.8)0.805 (0.7)0.52\*≥25 years45256 (12.4)46 (10.2)10 (2.1)7810 (12.7)9 (11.4)1 (1.3)SexFemale58072 (12.3)60 (10.2)0.0412 (2.1)0.16\*44057 (12.6)52 (11.7)0.245 (1.0)0.43\*Male28319 (6.6)17 (5.1)2 (0.7)24523 (9.4)22 (9.0)1 (0.3)^a^Includes all hospital employees (medical doctors, nurses, midwives, nursing students, medical and pharmacy students, interns, occasional workers, medical technologists, pharmacists, cleaning staff, and receptionists)^b^Pearson's χ^2^ test or \* Fisher's exact testTable 3Descriptive characteristics of healthcare workers from Antananarivo, Madagascar carrying *Staphylococcus aureus (S. aureus)* and methicillin-resistant *Staphylococcus aureus* (MRSA)Healthcare workers^a^ (*n* = 863)*S. aureus*MRSAVariableHCW^b^ group (n)n (%)n (%)Contact with patients74681 (10.9)14 (1.9)No contact with patients1057 (6.7)0Type of healthcare worker^c^ Physician18313 (7.1)1 (0.6) Nurse20323 (11.2)4 (2.0) Medical technologist183 (16.7)2 (11.1) Other (clerk, service assistant)91 (11.0)0Work place^c^ Outpatient department53 (60.0)0 Operating theatre61 (16.7)0 Ward8711 (12.5)2 (2.3) Other (administration)522 (3.9)0^a^ Includes all hospital employees: medical doctors, nurses, midwives, nursing students, medical and pharmacy students, interns, occasional workers, medical technologists, pharmacists, cleaning staff, and receptionists^b^ Healthcare worker^c^ For available dataTable 4Descriptive characteristics of healthcare workers from Antananarivo, Madagascar, with respect to carriage of *Staphylococcus aureus* (*S. aureus*) and methicillin-resistant *Staphylococcus aureus* (MRSA)Healthcare workers^a^ (*n* = 863)*S. aureus*MRSAVariablesTotal number (N^b)^HCW^c^ group (n)^b^n (%)*p* ^*d*^n (%)*p* ^*d*^Previous hospitalisation47371 (2.7)0.17\*01.0\*No previous hospitalisations147981689 (10.8)14 (1.7)Previous antimicrobial use^e^49331027 (8.7)0.184 (1.3)0.59\*No previous antimicrobial use91950659 (11.7)10 (2.0)Unknown108Skin infection21412115 (12.4)0.473 (2.5)0.44\*No skin infection130072474 (10.2)11 (1.5)Chronic illness^f^119689 (13.1)0.4400.62\*No chronic illness135877279 (10.2)14 (1.8)Nursing at home^g^48640341 (10.2)0.737 (1.70.84No nursing at home102544949 (10.9)7 (1.6)Living in dormatory190947 (7.5)0.300 (1.1)0.37\*Not living in dormatory130675782 (10.8)14 (2.7)Contact with animals ^h^76441741 (9.8)0.507 (1.7)0.90No contact with animals78444650 (11.2)7 (1.6)^a^ Includes all hospital employees: medical doctors, nurses, midwives, nursing students, medical and pharmacy students, interns, occasional workers, medical technologists, pharmacists, cleaning staff, and receptionists^b^ For available data^c^ Healthcare worker^d^ Pearson's χ^2^ test or \* Fishers exact test^e^During the last 6 months^f^ Chronic illness affecting the immune system^g^ Nursing sick family members at home^h^ Contact with pets and/or livestock such as cattle, poultry, pigs, sheep and goatsTable 5Descriptive characteristics of students from Antananarivo, Madagascar, with respect to carriage of *Staphylococcus aureus* (*S. aureus*) and methicillin-resistant *Staphylococcus aureus* (MRSA)Students (*n* = 685)*S. aureus*MRSAVariablesTotal number (N^a^)Student group (n)^a^n (%)*p* ^*b*^n (%)*p* ^*b*^Previous hospitalisation47102 (20.0)0.34\*01.0\*No previous hospitalisations147966378 (11.9)6 (0.9)Previous antimicrobial use^c^49318319 (10.4)0.991 (0.6)1.0\*No previous antimicrobial use91941343 (10.4)4 (1.0)Unknown108Skin infection214935 (5.4)0.04\*01.0\*No skin infection130057675 (13.0)6 (1.0)Chronic illness^d^119518 (15.7)0.3701.0\*No chronic illness135858667 (11.3)4 (0.7)Nursing at home^e^486839 (10.8)0.7701.0\*No nursing at home102557669 (12.0)6 (1.0)Living in dormatory190968 (8.2)0.2800.60\*Not living in dormatory130654967 (12.2)6 (1.1)Contact with animals ^f^76434741 (11.8)0.912 (0.6)0.43\*No contact with animals78433839 (11.4)4 (1.2)^a^For available data^b^ Pearson's χ^2^ test or \* Fishers exact test^c^During the last 6 months^d^ Chronic illness affecting the immune system^e^ Nursing sick family members at home^f^ Contact with pets and/or livestock such as cattle, poultry, pigs, sheep and goatsTable 6Multivariable logistic regression analyses of factors associated with nasal colonisation of healthcare workers and university students by *Staphylococcus aureus*VariableCategorynOR^a^ (95 % CI^b^)*p*AgeAge \<25 (years)4031Age \>25 (years)4521.47 (1.02--2.13)0.04SexFemale5801Male2830.57 (0.40--0.83)0.003OccupationStudent6851Healthcare worker8630.77 (0.54--1.11)0.16Antibiotics^c^No previous antimicrobial use9191Previous antimicrobial use4931.17 (0.91--1.49)0.22^a^OR, odds ratio, adjusted according to multivariable logistic regression^b^CI, confidence interval^c^During the last 6 months

In total, 21 *S. aureus* isolates (11.7 %) harboured PVL and 36 (21.1 %) harboured TSST-1. Ten (1.2 %) HCW and 11 (1.6 %) students carried PVL-positive strains in the anterior nares, while 20 HCW (2.3 %) and 16 (1.9 %) students carried TSST-1-positive strains (Table [7](#Tab7){ref-type="table"}).Table 7Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* isolated from students and healthcare workers from Antananarivo (*n* = 20)ST^a^CC^b^*spa* type^c^PVL^+^ (n) ^d^TSST-1^+^ (n) ^e^Healthcare workers (n)Students (n)88^f^88^g^t1860112488^g^88^g^t23930001n.d^h^n.d^h^t55620001n.d^h^n.d^h^t57720010n.d^h^n.d^h^t136530110^a^ Sequence type^b^ Clonal complex^c^ *Staphylococcal* protein A^d^ Panton-Valentine leukocidin gene present^e^ Toxic shock syndrome toxin gene present^f^ Automatically allocated by the Ridom SpaServer \[[@CR25]\]^g^ Retrieved from the literature \[[@CR37]\]^h^ Not determined

Recent findings indicate global occurrence of a new divergent *mecA* homologue, named *mecC* \[[@CR29]\]; therefore, all samples were also screened for the *mecC* gene. All MRSA isolates identified in this study harboured the *mecA* gene, but not the *mecC* gene.

*Staphylococcus* protein A gene (*spa*) typing was performed for all 20 MRSA isolates. Of the five different *spa* types identified, *spa* type t186 was the predominant clone (16/20, 80.0 %) among both HCW and students (Table [7](#Tab7){ref-type="table"}). The associated sequence type (ST) for *spa* types t186 and t2393 was ST-88. Eighteen MRSA-positive participants were treated with Mupirocin and were successfully decolonised. In accordance with the current guidelines of the Robert-Koch-Institute, Germany, one HCW required repeated Mupirocin treatment to ensure eradication \[[@CR28]\].

Discussion {#Sec12}
==========

To the best of our knowledge, this is the first study to report nasal *S. aureus* and MRSA carriage rates in HCW and non-medical university students in Madagascar. The overall prevalence of nasal *S. aureus* carriage identified in this study is lower than that reported in another study from Madagascar, which identified MSSA in 38 % of outpatients \[[@CR7]\].

The finding that nasal carriage of *S. aureus* is higher in females is in line with a study of HCW from Norway, which showed that female HCW had a 54 % increased risk of *S. aureus* nasal carriage *versus* non-HCW (OR, 1.54; 95 % CI, 1.09--2.19). However, the Norwegian study differed from the current study in terms of both study design and detection methods used \[[@CR30]\].

Data regarding nasal carriage of MRSA by African HCW are scarce. Studies of HCW from Ethiopia and Libya identified nasal carriage rates for MRSA of 14.1 % \[[@CR31]\] and 36.8 % \[[@CR32]\]), respectively, whereas a study from Kenya found a nasal carriage rate of 0 % \[[@CR33]\]. A study from São Tomé and Principe sampled HCW at two different time points and found that the MRSA prevalence ranged from 1.6 to 4.0 % \[[@CR34]\]. A systematic review of MRSA carriage by HCW in non-outbreak situations in Europe and the USA calculated a pooled MRSA colonisation rate of 1.8 % (95 % CI, 1.34--2.50 %) \[[@CR35]\]. Carriage rates identified by the individual studies in this particular review ranged from 0.2 to 15 %. Taken together, these studies show that MRSA carriage rates in HCW are highly variable.

PVL is a cytotoxin that causes dermonecrosis and lysis of human granulocytes and increases the adherence of *S. aureus* to the extracellular matrix \[[@CR36]\]. Evidence suggests that PVL is associated with staphylococcal skin and soft tissue infections and with severe necrotising pneumonia \[[@CR18]\]. As MRSA-colonised HCW may act as a source of infection in outbreak settings \[[@CR3]\], we sought to identify this virulence factor in all *S. aureus* isolates. Previous studies from Africa reported high rates for PVL in MSSA strains (ranging from 17 to 74 %) \[[@CR8], [@CR16]\]. A study from Gabon reported high PVL rates in both clinical isolates (54.7 %) and isolates obtained from asymptomatic carriers (40.5 %) \[[@CR21]\]. Finally, a study by Breurec et al. found that 30 % of clinical isolates from Antananarivo were PVL-positive \[[@CR8]\]. The comparatively moderate PVL-positivity rate (11.6 %) identified in our study is in contrast with that found in industrialised countries, in which PVL is rare; however, our findings support those of previous studies from sub-Saharan Africa \[[@CR8], [@CR16], [@CR21]\].

A recent study from Congo identified the TSST-1-encoding gene in 17.5 % of all *S. aureus* isolates obtained from HCW \[[@CR20]\]. We found even higher rates in both groups examined herein, suggesting that TSST-1 may be more prevalent in *S. aureus* strains from Africa than in strains from Europe, making infection control practices in Malagasy hospitals an urgent priority.

MRSA *spa* type t186 was the predominant clone identified in the current cohort, and the most common type identified in HCW. *Spa* type t186 was one of the clones previously circulating in hospital patients in Antananarivo, Madagascar \[[@CR15]\]. According to the RidomSpa Server database \[[@CR26]\], this clone occurs worldwide, and the automatically allocated sequence type ST-88 \[[@CR27]\] is predominant in West, Central and East Africa \[[@CR14]\]. The *spa* type t2393 identified herein was also identified in hospital isolates from Ghana, north-eastern Argentina and from a patient from Berlin with a travel history to Panama, whereas *spa* type t5562 was found in New Zealand isolates \[[@CR37]--[@CR40]\].

Limitations {#Sec13}
-----------

A lack of selective enrichment before culture on agar plates may explain the low prevalence of *S. aureus* detection. Also, *S. aureus* frequently colonises other sites on the skin, which were not swabbed in this study due to ethical and operational reasons \[[@CR41]\]. This may also account for the low rate of *S. aureus* detection.

The samples examined herein were collected by self-administered nasal swabbing; therefore, sampling may have not been carried out in the best possible way. However, other large, population-based studies of MRSA carriage in Europe were based on self-swabbing techniques, and nasal self-swabbing itself has been shown to be appropriate for the detection of *S. aureus* and MRSA \[[@CR42]--[@CR44]\].

A large part of our study population consisted of students; therefore, we may expect a lower prevalence of *S. aureus* in such healthy participants compared with that in outpatients or hospitalised patients.

It was our intention not to include high-risk groups such as children or people over the age of 69 years, and a group of healthy and relatively young students was used as a proxy for community controls. The relatively low number of *S. aureus* and MRSA isolates mean that the present study has low statistical power; therefore, we may not have detected any association between colonisation and risk factors such as skin lesions \[[@CR3]\].

Conclusion {#Sec14}
==========

In conclusion, this study provides a good overview of MRSA clones circulating in this particular region of Madagascar. The prevalence of MRSA in HCW and healthy students from Madagascar was low, and all *S. aureus* strains showed high resistance to penicillin, which is in line with other reports across the African continent. *Spa* type t186, which is the dominant clone on mainland Africa, was also the predominant MRSA clone identified in the current study population. The fairly high rates of TSST-1 and the presence of PVL-producing strains represent a potential reservoir and source for possible severe infection, which could lead to the emergence of successful MRSA clones. From a clinical point-of-view, MRSA screening programs in Africa are limited by a lack of facilities and a lack of qualified staff and financial resources. Antibiotic regimens to eradicate MRSA are expensive. However, general hygiene measures (e.g., hand washing) are both cheap and effective at preventing the spread of MRSA by HCW and should be promoted and performed diligently.
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